• Corpus ID: 51847757

DEVELOPMENT AND VALIDATION OF RP-HPLC-PDA METHOD FOR THE ESTIMATION OF MACITENTAN IN BULK AND TABLET DOSAGE FORMS.

@article{Unnisa2014DEVELOPMENTAV,
  title={DEVELOPMENT AND VALIDATION OF RP-HPLC-PDA METHOD FOR THE ESTIMATION OF MACITENTAN IN BULK AND TABLET DOSAGE FORMS.},
  author={Aziz Unnisa and Syed. Sadath Ali and Santosh Kumar.S},
  journal={Indo American Journal of Pharmaceutical Research},
  year={2014},
  volume={4},
  pages={3836-3843}
}
Article history The aim of the present study was to develop RP-HPLC-PDA method for the estimation of Macitentan in bulk and pharmaceutical dosage forms. The method uses an Inertsil (250 mm x 4.6, 5 m) with mobile phase consisting ofAcetonitrile: 10 mM Ammonium acetate (60:40 v/v) in an isocratic mode with an injection volume of 10μL and the eluents were monitored at 255 nm. The retention time of Macitentan 5.578 min, it showed linearity in the concentration range of 2-10 μg/mL with a good… 
2 Citations

Figures and Tables from this paper

Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations
Macitentan is an endothelin receptor antagonist drug used in the treatment of pulmonary arterial hypertension. A new, sensitive, simple, accurate and rapid ultra-performance liquid
High performance liquid chromatography method of macitentan related substances
The invention discloses a high performance liquid chromatography method of macitentan related substances. The method adopts a reversed phase chromatographic column and an ultraviolet detector, and

References

SHOWING 1-10 OF 11 REFERENCES
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.
  • O. Kummer, M. Haschke, S. Krähenbühl
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2009
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans
TLDR
Concentrations of total radioactivity in whole blood were lower compared to plasma, which indicates that macitentan and its metabolites poorly bind to or penetrate into erythrocytes.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple‐dose study in healthy subjects
TLDR
The present results support investigation of macitentan in the management of pulmonary arterial hypertension and ET‐1‐dependent pathologies and suggest an improved liver safety profile.
The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.
TLDR
Compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ET(A) with significant affinity for the ET(B) receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats.
Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
TLDR
The safety profile of macitentan appears to be superior with respect to hepatic safety and edema/fluid retention than bosentan and ambrisentan, respectively, and is similar when considering decrease in hemoglobin concentration.
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
TLDR
Macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats, which makes it a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation.
Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
TLDR
Macitentan is a competitive ERA with significantly slower receptor dissociation kinetics than the currently approved ERAs, which could contribute to an enhanced pharmacological activity of macitentan in ET-1-dependent pathologies.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
TLDR
Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.
An epidemiological study of pulmonary arterial hypertension
TLDR
All hospitalisations for pulmonary arterial hypertension (PAH) in the Scottish population were examined to determine the epidemiological features of PAH, and hospitalisation data from the Scottish Morbidity Record scheme gave higher prevalences of pulmonary arterIAL hypertension thanData from the expert centres (Scotland and France).
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
TLDR
The pharmacokinetic and tolerability profile of macitentan is consistent with a once-a-day dosing regimen and warrants further investigation in clinical studies.
...
...